What is Calyxo?
Calyxo Inc. is dedicated to advancing the treatment of kidney stone disease through the development of cutting-edge, minimally invasive medical devices. Its flagship technology, the CVAC System, is engineered to enhance the efficacy and safety of kidney stone removal, aiming to improve clinical outcomes for urologists and expedite patient recovery. The company's focus on improving patient care and surgical efficiency positions it as a key innovator in the urology sector.
How much funding has Calyxo raised?
Calyxo has raised a total of $124.3M across 4 funding rounds:
Series A
$1.6M
Series C
$32.7M
Series D
$50M
Series F
$40M
Series A (2018): $1.6M, investors not publicly disclosed
Series C (2022): $32.7M led by CRG and Questa Capital
Series D (2023): $50M supported by CRG, Avidity Partners, and Questa Capital
Series F (2026): $40M featuring Questa Capital, Avidity Partners, Janus Henderson Group, Crg, and Ally Bridge Group
Key Investors in Calyxo
Questa Capital
Questa Capital invests in innovative healthcare companies that aim to enhance patient experiences, reduce costs, and improve overall population health. They partner with exceptional teams to support the development of next-generation healthcare solutions, such as connected AEDs, telemedicine for opioid recovery, and advanced neurological therapies for children. Their portfolio includes companies like Avive, Bicycle Health, Calyxo, ClaritasRx, Cortica, and DispatchHealth, each focused on transforming healthcare delivery. Questa Capital is dedicated to advancing healthcare and enhancing lives through strategic investments.
Crg
CRG Group L.P. (CRG) is a global investment firm focused on enhancing healthcare through flexible growth capital solutions. With over $4 billion in institutional capital, CRG specializes in credit and select equity investments across consumer health, life sciences, and healthcare services & IT. The firm leverages decades of experience to create tailored financial strategies that foster sustainable growth for its partners.
Ally Bridge Group
Ally Bridge Group is a global healthcare investment management firm that specializes in high-impact life science innovation, managing over $6 billion in transactions since its inception in 2013. The firm operates from offices in New York and Hong Kong, focusing on both private equity and public equity strategies across the healthcare sector.
What's next for Calyxo?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Calyxo. This capital infusion is anticipated to fuel further research and development, scale manufacturing capabilities, and expand commercialization efforts for its CVAC System. The company is poised to solidify its market position and potentially redefine standards of care in kidney stone treatment, driven by its commitment to innovation and patient well-being.
See full Calyxo company page
